The best overview for all products and delivery methods for the company were the analyst reports by Arrowhead and Chardan Capital markets - I'd start with those if you can still find them, they were published in 2014.
Alferon-N and Alferon LDO experimental are very interesting drugs. LDO has huge potential. There was an ape study a number of years ago where LDO beat the heck out of tamiflu for flu prevention. Here is a reference pr. http://hemispherx.net/content/investor/default.asp?goto=799
re: you business concern. They are a tiny biotech trying to do great things. Creating drugs, the facilities to produce them and getting them approved is very complicated business. Biotech sector is a risky business - high risk = high reward. Often, things do not go smoothly.
News 
Market Data 
Discover 
